London · Delayed Price · Currency is GBP · Price in GBX EKF Diagnostics Holdings Earnings Call Transcripts
Fiscal Year 2025
-
2025 was a foundational year with 3% revenue growth, improved gross margin, and strong EBITDA. Strategic execution, share buybacks, and expansion in key markets set the stage for accelerated growth, with Life Sciences and BHB segments poised for further gains.
-
Revenue and profit remained stable year-over-year, with gross margin improving to 50% and EBITDA up 7.4%. Strategic investments in production and Life Sciences, new contracts in growth markets, and a continued share buyback support long-term growth targets.
Fiscal Year 2024
-
Revenue reached £50.2M with gross margin up to 48% and adjusted EBITDA at £11.3M. Strong cash generation supports a five-year plan targeting £80M+ revenue and £20M+ EBITDA by 2029, with growth focused on haemoglobin, fermentation, and BHB.